{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:07:27Z","timestamp":1789506447679,"version":"build-2803163510"},"reference-count":210,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The complement system is the primary defense mechanism against pathogens, acting through opsonization, the membrane attack complex, and classical, lectin, or alternative pathways. These pathways result in the production of key complement components, including C3a (complement component), C5a, and C3b, which recruit inflammatory cells. Complement dysregulation leads to renal disease through the overproduction of anaphylatoxins or inappropriate formation of the membrane attack complex. The levels of complement components have been shown to be useful as predictive markers in acute kidney injury, especially in conditions of alternative pathway activation, and in diseases of immune complex pathology such as lupus nephritis and IgA nephropathy. Genetic defects in complement regulatory proteins result in diseases such as C3 glomerulopathy or atypical hemolytic uremic syndrome, in which uncontrolled C3 convertase activity results in renal failure. Therapeutic interventions targeting complement components, including eculizumab or pegcetacoplan, improve patient outcomes in atypical hemolytic uremic syndrome and C3 glomerulopathy, respectively, while other interventions improve renal function in IgA nephropathy. These findings underscore the dual role of the complement system, which is not only implicated in the progression of renal diseases but also provides the potential for the development of therapeutic interventions for the treatment of various forms of nephropathy.<\/jats:p>","DOI":"10.3390\/ijms27083466","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:49:02Z","timestamp":1776070142000},"page":"3466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies"],"prefix":"10.3390","volume":"27","author":[{"given":"Patryk","family":"Jesio\u0142owski","sequence":"first","affiliation":[{"name":"Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"},{"name":"Transplantation and Nephrology Student Scientific Association, Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Krzywda","sequence":"additional","affiliation":[{"name":"Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Furma\u0144czyk-Zawiska","sequence":"additional","affiliation":[{"name":"Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-1497","authenticated-orcid":false,"given":"Magdalena","family":"Durlik","sequence":"additional","affiliation":[{"name":"Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5414\/CN107220","article-title":"Therapeutic regulation of complement in patients with renal disease\u2014Where is the promise?","volume":"77","author":"Thurman","year":"2012","journal-title":"Clin. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ai.2021.09.001","article-title":"Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics","volume":"152","author":"Freiwald","year":"2021","journal-title":"Adv. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1159\/000538241","article-title":"The Complement C3a and C5a Signaling in Renal Diseases: A Bridge between Acute and Chronic Inflammation","volume":"148","author":"Buelli","year":"2024","journal-title":"Nephron"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Heidenreich, K., Goel, D., Priyamvada, P.S., Kulkarni, S., Chakurkar, V., Khullar, D., Singh, R., Bale, C., and Zipfel, P.F. (2024). C3 glomerulopathy: A kidney disease mediated by alternative pathway deregulation. Front. Nephrol., 4.","DOI":"10.3389\/fneph.2024.1460146"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kesarwani, V., Bukhari, M.H., Kahlenberg, J.M., and Wang, S. (2024). Urinary complement biomarkers in immune-mediated kidney diseases. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1357869"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ekir.2016.06.005","article-title":"Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways","volume":"1","author":"Bomback","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_8","first-page":"822","article-title":"Blocking the alternative complement pathway","volume":"15","author":"Crunkhorn","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, M., Jia, B.B., and Li, M.F. (2022). Complement C3 and Activated Fragment C3a Are Involved in Complement Activation and Anti-Bacterial Immunity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.813173"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2102787118","DOI":"10.1073\/pnas.2102787118","article-title":"C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases","volume":"118","author":"Zwarthoff","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1073\/pnas.1616998114","article-title":"Structure and activation of C1, the complex initiating the classical pathway of the complement cascade","volume":"114","author":"Mortensen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-724-2_4","article-title":"Classical complement pathway components C1r and C1s: Purification from human serum and in recombinant form and functional characterization","volume":"1100","author":"Rossi","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16494","DOI":"10.1074\/jbc.M116.722017","article-title":"Solution Structures of Complement C2 and Its C4 Complexes Propose Pathway-specific Mechanisms for Control and Activation of the Complement Proconvertases","volume":"291","author":"Mortensen","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"F650","DOI":"10.1152\/ajprenal.00130.2019","article-title":"Urine complement activation fragments are increased in patients with kidney injury after cardiac surgery","volume":"317","author":"Laskowski","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brandwijk, R.J., Michels, M.A., van Rossum, M., de Nooijer, A.H., Nilsson, P.H., de Bruin, W.C., and Toonen, E.J. (2022). Pitfalls in complement analysis: A systematic literature review of assessing complement activation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1007102"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.4049\/jimmunol.1500087","article-title":"Structural Basis for the Function of Complement Component C4 within the Classical and Lectin Pathways of Complement","volume":"194","author":"Mortensen","year":"2015","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1038\/s41467-023-39788-5","article-title":"Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains","volume":"14","author":"Abendstein","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.12416","article-title":"Interaction of lectin pathway of complement-activating pattern recognition molecules with mycobacteria","volume":"178","author":"Bartlomiejczyk","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1074\/jbc.M606326200","article-title":"Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway","volume":"282","author":"Wallis","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117238","DOI":"10.1016\/j.ejmech.2025.117238","article-title":"Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3","volume":"289","author":"Nakhla","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fromell, K., Adler, A., \u00c5man, A., Manivel, V.A., Huang, S., D\u00fchrkop, C., Sandholm, K., Ekdahl, K.N., and Nilsson, B. (2020). Assessment of the Role of C3(H2O) in the Alternative Pathway. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00530"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E534","DOI":"10.1073\/pnas.1612385114","article-title":"Properdin binding to complement activating surfaces depends on initial C3b deposition","volume":"114","author":"Harboe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2215\/CJN.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.molimm.2010.05.007","article-title":"Complement. control protein factor H: The good, the bad, and the inadequate","volume":"47","author":"Ferreira","year":"2010","journal-title":"Mol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement. System Part. I\u2014Molecular Mechanisms of Activation and Regulation. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00262"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.kint.2022.07.035","article-title":"Factor H related proteins modulate complement activation on kidney cells","volume":"102","author":"Renner","year":"2022","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1038\/s41598-026-36417-1","article-title":"Urinary complement C3 fragment levels and their clinical relevance in MPO-ANCA-associated vasculitis","volume":"16","author":"Hu","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zwarthoff, S.A., Berends, E.T., Mol, S., Ruyken, M., Aerts, P.C., J\u00f3zsi, M., De Haas, C.J., Rooijakkers, S.H., and Gorham, R.D. (2018). Functional Characterization of Alternative and Classical Pathway C3\/C5 Convertase Activity and Inhibition Using Purified Models. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01691"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","article-title":"Membrane attack by complement: The assembly and biology of terminal complement complexes","volume":"51","author":"Tegla","year":"2011","journal-title":"Immunol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"117238","DOI":"10.1016\/j.cca.2023.117238","article-title":"The complement system testing in clinical laboratory","volume":"541","author":"Ding","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000529734","article-title":"Measurement of Complement Activation via Plasma-Soluble C5b-9 Comparison with Terminal Complement Complex Staining in a Series of Kidney Biopsies","volume":"48","author":"Wijaya","year":"2023","journal-title":"Kidney Blood Press. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Qi, R., and Qin, W. (2022). Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.811696"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.63.12.30","article-title":"An Evaluation of the Complement-Regulating Activities of Human Complement Factor H (FH) Variants Associated with Age-Related Macular Degeneration","volume":"63","author":"Biggs","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhao, F., Afonso, S., Lindner, S., Hartmann, A., L\u00f6schmann, I., Nilsson, B., Ekdahl, K.N., Weber, L.T., Habbig, S., and Schalk, G. (2019). C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01030"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Michels, M.A., Volokhina, E.B., van de Kar, N.C., and van den Heuvel, L.P. (2022). Challenges in diagnostic testing of nephritic factors. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1036136"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4049\/jimmunol.178.1.352","article-title":"Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay","volume":"178","author":"Harris","year":"2007","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coi.2021.04.005","article-title":"Membrane cofactor protein (MCP.; CD46): Deficiency states and pathogen connections","volume":"72","author":"Liszewski","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.4049\/jimmunol.168.12.6298","article-title":"Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells","volume":"168","author":"Liszewski","year":"2002","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-023-36441-z","article-title":"Structural basis for membrane attack complex inhibition by CD59","volume":"14","author":"Couves","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.2400194","article-title":"The Crystal Structure of the Michaelis-Menten Complex of C1 Esterase Inhibitor and C1s Reveals Novel Insights into Complement Regulation","volume":"213","author":"Garrigues","year":"2024","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hurler, L., Toonen, E.J., Kajd\u00e1csi, E., van Bree, B., Brandwijk, R.J., de Bruin, W., Lyons, P.A., Bergamaschi, L., Sinkovits, G., and Cervenak, L. (2022). Distinction of early complement classical and lectin pathway activation via quantification of C1s\/C1-INH and MASP-1\/C1-INH complexes using novel ELISAs. Front. Immunol., 13, Erratum in Front. Immunol.\u00a02025, 16, 1561850.","DOI":"10.3389\/fimmu.2025.1561850"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00467-012-2183-z","article-title":"Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding","volume":"27","author":"Volokhina","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Haque, A., Cortes, C., Alam, M.N., Sreedhar, M., Ferreira, V.P., and Pangburn, M.K. (2020). Characterization of Binding Properties of Individual Functional Sites of Human Complement Factor H. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01728"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Slagle, A.K., Ghiringhelli Borsa, N., Wang, K., Taylor, A.O., Meyer, N.C., Jones, M.B., Walls, W.D., Nelson, A.F., Roberts, S.M., and Sun, M. (2025). Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1589674"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2020081224","article-title":"IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome","volume":"32","author":"Cugno","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sinkovits, G., Mez\u0151, B., R\u00e9ti, M., M\u00fcller, V., Iv\u00e1nyi, Z., G\u00e1l, J., Gopcsa, L., Rem\u00e9nyi, P., Szathm\u00e1ry, B., and Lakatos, B. (2021). Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.663187"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1681\/ASN.2007070744","article-title":"IL-6\/IL-6R axis plays a critical role in acute kidney injury","volume":"19","author":"Barkan","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1186\/cc9289","article-title":"Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery","volume":"14","author":"Dennen","year":"2010","journal-title":"Crit. Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13613-016-0157-1","article-title":"Knockout of interleukin-17A protects against sepsis-associated acute kidney injury","volume":"6","author":"Luo","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"742","DOI":"10.23876\/j.krcp.22.063","article-title":"The roles of interleukin-17A in risk stratification and prognosis of patients with sepsis-associated acute kidney injury","volume":"42","author":"Jin","year":"2023","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1681\/ASN.2008020170","article-title":"IL-18 contributes to renal damage after ischemia-reperfusion","volume":"19","author":"Wu","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/cc6972","article-title":"Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: A prospective observational cohort study","volume":"12","author":"Haase","year":"2008","journal-title":"Crit. Care"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wu, X., You, D., Cui, J., Yang, L., Lin, L., Chen, Y., Xu, C., Lian, G., and Wan, J. (2022). Reduced Neutrophil Extracellular Trap Formation During Ischemia Reperfusion Injury in C3 KO Mice: C3 Requirement for NETs Release. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.781273"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/0886022X.2019.1677248","article-title":"Effect of anti-C5 antibody on recuperation from ischemia\/reperfusion-induced acute kidney injury","volume":"41","author":"Stark","year":"2019","journal-title":"Ren. Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"326","DOI":"10.34067\/KID.0000000000000077","article-title":"Urine Complement Factor Ba Is Associated with AKI in Critically Ill Children","volume":"4","author":"Stenson","year":"2023","journal-title":"Kidney360"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ekir.2024.11.023","article-title":"Urinary Complement. Factor. Ba: A New Tool. for Early Detection of Acute Kidney Injury","volume":"10","author":"Timmermans","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ekir.2024.11.030","article-title":"Urine Complement Factor Ba Identifies Persistent Acute Kidney Injury and Organ Failures in Critically Ill Adults","volume":"10","author":"Stenson","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/ndt\/gfm638","article-title":"Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children","volume":"23","author":"Washburn","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.34067\/KID.0004542021","article-title":"Complement Activation Fragments Are Increased in Critically Ill Pediatric Patients with Severe AKI","volume":"2","author":"Stenson","year":"2021","journal-title":"Kidney360"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1002\/jmv.27077","article-title":"Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state","volume":"93","author":"Henry","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lasorsa, F., Rutigliano, M., Milella, M., d\u2019Amati, A., Crocetto, F., Pandolfo, S.D., Barone, B., Ferro, M., Spilotros, M., and Battaglia, M. (2024). Ischemia\u2013Reperfusion Injury in Kidney Transplantation: Mechanisms and Potential Therapeutic Targets. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084332"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.kint.2018.10.009","article-title":"Nicholson, Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells","volume":"95","author":"Smith","year":"2019","journal-title":"Kidney Int."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Renaudineau, Y., Brooks, W., and Belliere, J. (2023). Lupus Nephritis Risk Factors and Biomarkers: An. Update. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914526"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, X., Fu, S., Yu, J., Tang, D., Wu, H., and Xu, Z. (2023). Renal C4d is a potential biomarker of disease activity and severity in pediatric lupus nephritis patients. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1193917"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ayano, M., and Horiuchi, T. (2023). Complement as a Biomarker for Systemic Lupus Erythematosus. Biomolecules, 13.","DOI":"10.3390\/biom13020367"},{"key":"ref_68","first-page":"16","article-title":"Urinary levels of IL-6 in patients with active lupus nephritis","volume":"40","author":"Iwano","year":"1993","journal-title":"Clin. Nephrol."},{"key":"ref_69","first-page":"29","article-title":"Serum and Urinary Interleukin-6 in Assessment of Renal Activity in Egyptian Patients with Systemic Lupus Erythematosus","volume":"9","author":"Lotfi","year":"2016","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s43166-024-00268-3","article-title":"Elsayed, Interleukin-17 as a biomarker for lupus nephritis: Correlation with disease activity indices and histopathological classification","volume":"51","author":"Ahmed","year":"2024","journal-title":"Egypt. Rheumatol. Rehabil."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.amjms.2017.01.005","article-title":"Complement Alternative Pathway\u2019s Activation in Patients with Lupus Nephritis","volume":"353","author":"Song","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e000263","DOI":"10.1136\/lupus-2018-000263","article-title":"Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e000236","DOI":"10.1136\/lupus-2017-000236","article-title":"Cell-bound complement activation products in SLE","volume":"4","author":"Li","year":"2017","journal-title":"Lupus Sci. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Martin, M., Trattner, R., Nilsson, S.C., Bj\u00f6rk, A., Zickert, A., Blom, A.M., and Gunnarsson, I. (2020). Plasma C4d Correlates with C4d Deposition in Kidneys and with Treatment Response in Lupus Nephritis Patients. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.582737"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0961203311422093","article-title":"Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: A pilot study","volume":"21","author":"Batal","year":"2012","journal-title":"Lupus"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-017-1470-2","article-title":"Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus","volume":"19","author":"Martin","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.ekir.2021.05.029","article-title":"The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare","volume":"6","author":"Toy","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"sfae077","DOI":"10.1093\/ckj\/sfae077","article-title":"Prognostic factors and validation of the histologic chronicity score for C3 glomerulopathy: A registry analysis","volume":"17","author":"Mirioglu","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajmg.c.31986","article-title":"C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease","volume":"190","author":"Heiderscheit","year":"2022","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"101258","DOI":"10.1016\/j.xkme.2026.101258","article-title":"C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies","volume":"8","author":"Mashayekhi","year":"2026","journal-title":"Kidney Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4049\/jimmunol.1801042","article-title":"IL-17 in Renal Immunity and Autoimmunity","volume":"201","author":"Biswas","year":"2018","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Su, H., Lei, C.T., and Zhang, C. (2017). Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00405"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00467-024-06377-7","article-title":"Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children","volume":"39","author":"Ueda","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00467-021-05221-6","article-title":"Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort","volume":"37","author":"Michels","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2215\/CJN.0000000000000252","article-title":"Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN","volume":"18","author":"Meuleman","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ekir.2023.11.025","article-title":"Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy","volume":"9","author":"Hauer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative Complement Pathway Inhibition with Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","article-title":"Eculizumab and recurrent C3 glomerulonephritis","volume":"28","author":"Gurkan","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of Clinical Response to Eculizumab in Patients with C3 Glomerulopathy","volume":"72","author":"Lapeyraque","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Welte, T., Arnold, F., Westermann, L., Rottmann, F.A., Hug, M.J., Neumann-Haefelin, E., and Ganner, A. (2023). Eculizumab as a treatment for C3 glomerulopathy: A single-center retrospective study. BMC Nephrol., 24.","DOI":"10.1186\/s12882-023-03058-9"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/ajh.26854","article-title":"Complement-driven hemolytic uremic syndrome","volume":"98","author":"Leon","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s10020-025-01331-1","article-title":"Pathogenic cytokines in thrombotic microangiopathies: Molecular insights and therapeutic targets","volume":"31","author":"Obeagu","year":"2025","journal-title":"Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Blasco, M., Guill\u00e9n-Olmos, E., Diaz-Ricart, M., and Palomo, M. (2022). Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Front. Med., 9.","DOI":"10.3389\/fmed.2022.811504"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40620-022-01465-z","article-title":"Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: Analysis from the Global aHUS registry","volume":"36","author":"Halimi","year":"2023","journal-title":"J. Nephrol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ekir.2024.06.020","article-title":"Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab","volume":"9","author":"Schaefer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mocanu, V.D., Sorohan, B.M., Micu, E.G., B\u0103l\u0103nic\u0103, S., Obri\u015fc\u0103, B., Jurubi\u021b\u0103, R.A., Achim, C.A., Lungu, A.C., C\u0103pu\u015f\u0103, C.S., and Mircescu, G. (2025). Terminal complement inhibition in atypical haemolytic uremic syndrome: A single-centre experience. Front. Pharmacol., 16, Correction in Front. Pharmacol.\u00a02025, 16, 1760223.","DOI":"10.3389\/fphar.2025.1760223"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s40620-025-02366-7","article-title":"Clinical and genetic characteristics of patients diagnosed with atypical hemolytic uremic syndrome (aHUS): Epidemiological data from the Belgian cohort of the Global aHUS Registry","volume":"38","author":"Massart","year":"2025","journal-title":"J. Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: An observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40620-020-00920-z","article-title":"Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: Analysis of a Brazilian cohort","volume":"34","author":"Neto","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int."},{"key":"ref_108","first-page":"1","article-title":"Advances in the treatment of IgA nephropathy with biological agents","volume":"10","author":"Zhuang","year":"2024","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e15125","DOI":"10.7717\/peerj.15125","article-title":"Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis","volume":"11","author":"Niu","year":"2023","journal-title":"PeerJ"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wang, Z., Xie, X., Li, J., Zhang, X., He, J., Wang, M., Lv, J., and Zhang, H. (2021). Complement Activation Is Associated with Crescents in IgA Nephropathy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.676919"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/ndt\/gfac024","article-title":"The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: A cohort study","volume":"37","author":"Wang","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Chiu, Y.L., Lin, W.C., Shu, K.H., Fang, Y.W., Chang, F.C., Chou, Y.H., Wu, C.F., Chiang, W.C., Lin, S.L., and Chen, Y.M. (2021). Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA(1) Antibody in IgA Nephropathy Patients. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.638309"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/ndt\/gfad163","article-title":"Circulating alternative pathway complement cleavage factor Bb is associated with vascular lesions and outcomes in IgA nephropathy","volume":"38","author":"Jullien","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ekir.2022.12.023","article-title":"Elevated Urinary IL-6 Predicts the Progression of IgA Nephropathy","volume":"8","author":"Zhao","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_116","first-page":"186","article-title":"T lymphocytes in IgA nephropathy","volume":"20","author":"Tang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/00365513.2011.652158","article-title":"Imbalance of regulatory T cells to Th17 cells in IgA nephropathy","volume":"72","author":"Lin","year":"2012","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zagorec, N., Horvati\u0107, I., Kasumovi\u0107, D., Osmani, B., Sovi\u0107, S., Niki\u0107, J., Hora\u010dek, M., \u0160enjug, P., Gale\u0161i\u0107, K., and Gale\u0161i\u0107 Ljubanovi\u0107, D. (2024). C4d Is an Independent Predictor of the Kidney Failure in Primary IgA Nephropathy. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175338"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.xkme.2021.06.009","article-title":"Glomerular C4d Deposition and Kidney Disease Progression in IgA Nephropathy: A Systematic Review and Meta-analysis","volume":"3","author":"Jiang","year":"2021","journal-title":"Kidney Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40364-024-00619-4","article-title":"Blood and urine biomarkers of disease progression in IgA nephropathy","volume":"12","author":"Duan","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2019080851","article-title":"Anti-Factor B Antibodies and Acute Postinfectious GN in Children","volume":"31","author":"Chauvet","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Barnum, S.R., Bubeck, D., and Schein, T.N. (2020). Soluble Membrane Attack Complex: Biochemistry and Immunobiology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.585108"},{"key":"ref_124","first-page":"6","article-title":"Circulating levels of cytokines in poststreptococcal glomerulonephritis","volume":"47","author":"Soto","year":"1997","journal-title":"Clin. Nephrol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.ekir.2023.08.022","article-title":"Diffuse Endocapillary Glomerulonephritis in a Child with IL-17RA Deficiency Emphasizes the Pivotal Role of the Complement Cascade and Anaphylatoxins","volume":"8","author":"Grapin","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1089\/ars.2021.0125","article-title":"The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease","volume":"37","author":"Tan","year":"2022","journal-title":"Antioxid. Redox Signal."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Jiang, S., Di, D., Jiao, Y., Zou, G., Gao, H., and Li, W. (2022). Complement Deposition Predicts Worsening Kidney Function and Underlines the Clinical Significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.868127"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Xu, Z., Tao, L., and Su, H. (2022). The Complement. System in Metabolic-Associated Kidney Diseases. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.902063"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e156748","DOI":"10.1172\/jci.insight.156748","article-title":"Deficiency of CFB attenuates renal tubulointerstitial damage by inhibiting ceramide synthesis in diabetic kidney disease","volume":"7","author":"Sun","year":"2022","journal-title":"JCI Insight"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e147716","DOI":"10.1172\/jci.insight.147716","article-title":"Complement factor B in high glucose\u2013induced podocyte injury and diabetic kidney disease","volume":"6","author":"Lu","year":"2021","journal-title":"JCI Insight"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Zhang, L., Xu, F., and Hou, L. (2024). IL-6 and diabetic kidney disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1465625"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41598-019-38811-4","article-title":"Interleukin 17A promotes diabetic kidney injury","volume":"9","author":"Ma","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"104956","DOI":"10.1016\/j.jbc.2023.104956","article-title":"Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies","volume":"299","author":"Struijf","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Menne, J., Delmas, Y., Fakhouri, F., Licht, C., Lommel\u00e9, \u00c5., Minetti, E.E., Prov\u00f4t, F., Rondeau, E., Sheerin, N.S., and Wang, J. (2019). Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1314-1"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Carrillo Infante, C., and Mujeebuddinand, A. (2025). Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0332073"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"i115","DOI":"10.1093\/ndt\/gfw353","article-title":"Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome","volume":"32","author":"Verhave","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Fortunato","year":"2021","journal-title":"Kidney Int."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"100855","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","article-title":"A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nfelder, K., K\u00fchne, L., Schulte-Kemna, L., Kaufeld, J., Rohn, H., Kribben, A., Schr\u00f6ppel, B., Brinkk\u00f6tter, P.T., and G\u00e4ckler, A. (2024). Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03638-3"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1038\/s41467-022-33003-7","article-title":"Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors","volume":"13","author":"Lamers","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_146","unstructured":"Apellis Pharmaceuticals, Inc. (2021). A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis, Apellis Pharmaceuticals, Inc."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"101189","DOI":"10.1016\/j.xkme.2025.101189","article-title":"Early Experience with Iptacopan for Recurrent IgA Nephropathy After Kidney Transplantation","volume":"8","author":"Bucay","year":"2026","journal-title":"Kidney Med."},{"key":"ref_150","unstructured":"Achillion Pharmaceiuticals, Inc. (2017). A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G), with an Open-label Extension, Alexion Pharmaceuticals, Inc."},{"key":"ref_151","unstructured":"Achillion Pharmaceiuticals, Inc. (2018). An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471, Alexion Pharmaceuticals, Inc."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"CADTH (2023). Reimbursement Reviews and Recommendations, in Avacopan (Tavneos): CADTH Reimbursement Recommendation: Indication: For the Adjunctive Treatment of Adult Patients with Severe Active Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis (Granulomatosis with Polyangiitis and Microscopic Polyangiitis) in Combination with Standard Background Therapy Including Glucocorticoids. Avacopan Does Not Eliminate Glucocorticoid Use, Canadian Agency for Drugs and Technologies in Health.","DOI":"10.51731\/cjht.2023.762"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"He","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Scheinberg","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/j.ekir.2022.04.074","article-title":"POS-052 Two Phase III Trials Evaluating Crovalimab in Patients with Atypical Haemolytic Uraemic Syndrome (aHUS): COMMUTE-A and COMMUTE-p","volume":"7","author":"Sheerin","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_161","unstructured":"ClinicalTrials.gov (2025, November 25). A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants with Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03347396."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/10600280221138802","article-title":"Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis","volume":"57","author":"Moore","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12185-024-03842-9","article-title":"Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease","volume":"120","author":"Miyakawa","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1097\/HS9.0000000000000879","article-title":"Sutimlimab for the Treatment of Cold Agglutinin Disease","volume":"7","author":"Berentsen","year":"2023","journal-title":"Hemasphere"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/ajh.27358","article-title":"Cost-effectiveness of sutimlimab in cold agglutinin disease","volume":"99","author":"Ito","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_167","unstructured":"ClinicalTrials.gov (2026, February 12). A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects with C3 Glomerulopathy (C3G), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05647811."},{"key":"ref_168","unstructured":"ClinicalTrials.gov (2026, February 13). A Phase II, Open-Label Study of NM8074 in Patients with Atypical Hemolytic Uremic Syndrome (aHUS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05684159."},{"key":"ref_169","unstructured":"ClinicalTrials.gov (2026, February 13). A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06226662."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"152876","DOI":"10.1016\/j.imbio.2025.152876","article-title":"Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen","volume":"230","author":"McCaleb","year":"2025","journal-title":"Immunobiology"},{"key":"ref_171","unstructured":"ClinicalTrials.gov (2026, February 12). A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants with Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05797610."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/hematology.2023000501","article-title":"Medical consult: aHUS, TTP? How to distinguish and what to do","volume":"2023","author":"Story","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jth.13189","article-title":"The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies","volume":"14","author":"Phillips","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3346\/jkms.2016.31.10.1516","article-title":"Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea","volume":"31","author":"Cheong","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_175","first-page":"e20240087","article-title":"Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): An expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN)","volume":"47","author":"Vaisbich","year":"2025","journal-title":"J. Bras. Nefrol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Musalem, P., Bascur, N., Sep\u00falveda, R.A., Krall, P., Lazcano, A., Navarro, G., Rojo, A., and Grandy, J. (2026). Diagnosis and treatment of complement-mediated thrombotic microangiopathies: Consensus of the Genetic Diseases Committee of the Chilean Society of Nephrology. BMC Nephrol., 27.","DOI":"10.1186\/s12882-025-04739-3"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"101198","DOI":"10.1016\/j.xkme.2025.101198","article-title":"Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients with Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study)","volume":"8","author":"Hanna","year":"2026","journal-title":"Kidney Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","article-title":"Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation","volume":"7","author":"Moyer","year":"2023","journal-title":"Blood Adv."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1007\/s00467-024-06373-x","article-title":"Anti-CFH-associated hemolytic uremic syndrome: Do we still need plasma exchange?","volume":"39","author":"Ferri","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/17474086.2024.2365169","article-title":"Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: A narrative review of the literature","volume":"17","author":"Fortunato","year":"2024","journal-title":"Expert. Rev. Hematol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/17512433.2023.2209317","article-title":"Pharmacological and clinical profile of ravulizumab 100 mg\/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"16","author":"Ariceta","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00467-024-06279-8","article-title":"Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome","volume":"39","author":"Thangaraju","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/ndt\/gfad182","article-title":"C3G and Ig-MPGN\u2014Treatment standard","volume":"39","author":"Noris","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2024.10.023","article-title":"Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy","volume":"10","author":"Nester","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Mirioglu, S., and Ozturk, S. (2025). Novel treatment strategies for C3 glomerulopathy: Complement blockade. Int. Urol. Nephrol.","DOI":"10.1007\/s11255-025-04939-8"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Nam, K.H., Kie, J.H., Lee, M.J., Chang, T.I., Kang, E.W., Kim, D.W., Lim, B.J., Park, J.T., Kwon, Y.E., and Kim, Y.L. (2014). Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101935"},{"key":"ref_191","unstructured":"ClinicalTrials.gov (2026, February 14). A Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IGAN), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03608033."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"International Society of Nephrology (2025). KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int., 108, S1\u2013S71.","DOI":"10.1016\/j.kint.2025.04.004"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s12325-025-03187-7","article-title":"An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy","volume":"42","author":"Glassock","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"ii47","DOI":"10.1093\/ckj\/sfad201","article-title":"Expanding options of supportive care in IgA nephropathy","volume":"16","author":"Maixnerova","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Halacova, N., Brndiarova, M., Slenker, B., Ruzinak Bobcakova, A., Schniederova, M., Markocsy, A., Urbancikova, I., and Jesenak, M. (2026). Complement Inhibitors and the Risk of (Breakthrough) Infections\u2014Critical Analysis and Preventive Strategies. Biologics, 6.","DOI":"10.3390\/biologics6010003"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.13156","article-title":"Alternative pathway diagnostics","volume":"313","author":"Thurman","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Wada, Y., Kamata, M., Miyasaka, R., Abe, T., Kawamura, S., Takeuchi, K., Aoyama, T., Oda, T., and Takeuchi, Y. (2023). Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098432"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.pcl.2022.08.001","article-title":"Acute Postinfectious Glomerulonephritis","volume":"69","author":"Duong","year":"2022","journal-title":"Pediatr. Clin. North. Am."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1053\/j.ajkd.2016.06.026","article-title":"Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated with Anti-Factor H Autoantibody","volume":"68","author":"Chehade","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Chehade, H., Guzzo, G., Cachat, F., Rotman, S., Teta, D., Pantaleo, G., Sadallah, S., Sharma, A., Rosales, I.A., and Tolkoff-Rubin, N. (2021). Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports. Front. Med., 8.","DOI":"10.3389\/fmed.2021.663258"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Delaura, I.F., Gao, Q., Anwar, I.J., Abraham, N., Kahan, R., Hartwig, M.G., and Barbas, A.S. (2022). Complement-targeting therapeutics for ischemia-reperfusion injury in transplantation and the potential for ex vivo delivery. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1000172"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Trambas, I.A., Coughlan, M.T., and Tan, S.M. (2023). Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108758"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1038\/s41467-025-62101-5","article-title":"Urinary Complement proteome strongly linked to diabetic kidney disease progression","volume":"16","author":"Moon","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ekir.2025.04.061","article-title":"Complement Proteins Identify Rapidly Progressive Diabetic Kidney Disease","volume":"10","author":"Yun","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41598-024-84900-4","article-title":"Complement classical and alternative pathway activation contributes to diabetic kidney disease progression: A glomerular proteomics on kidney biopsies","volume":"15","author":"Yang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/db19-0043","article-title":"Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility","volume":"69","author":"Tan","year":"2020","journal-title":"Diabetes"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: A prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:04:50Z","timestamp":1776071090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":210,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27083466"],"URL":"https:\/\/doi.org\/10.3390\/ijms27083466","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}